PMID- 32227501
OWN - NLM
STAT- MEDLINE
DCOM- 20210708
LR  - 20220531
IS  - 1745-4514 (Electronic)
IS  - 0145-8884 (Linking)
VI  - 45
IP  - 3
DP  - 2021 Mar
TI  - The effect of dried Ziziphus vulgaris on glycemic control, lipid profile, 
      Apo-proteins and hs-CRP in patients with type 2 diabetes mellitus: A randomized 
      controlled clinical trial.
PG  - e13193
LID - 10.1111/jfbc.13193 [doi]
AB  - We aimed to evaluate the effect of dried Ziziphus vulgaris [Z. vulgaris] 
      consumption on liver enzymes, blood pressure, inflammatory status, glycemic 
      control, and lipid concentrations in type 2 diabetes patients. Seventy-six 
      diabetic participants (aged 20-65 years) randomly assigned to intervention 
      (n = 38) and placebo (n = 38) groups. The intervention group received 30 g/day 
      dried Z. vulgaris for 12 weeks. At the end of the study, there was a significant 
      reduction in the percentage change of weight, body mass index [BMI], insulin, 
      homeostasis model assessment-insulin resistance [HOMA-IR], Apoprotein B100 
      [ApoB100], and high-sensitive c-reactive protein [hs-CRP] in the intervention 
      group compared to the controls. Also, increased values of quantitative insulin 
      check index [QUICKI] and Apoprotein A-I [ApoA-I] in Z. vulgaris group compared to 
      the controls were observed. In conclusion, consumption of dried Z. vulgaris fruit 
      could have beneficial effects on improving the glycemic control and reducing the 
      cardiovascular risk factors in the diabetic patients. PRACTICAL APPLICATIONS: In 
      the present study we found that consumption of 30 g/day dried Z. vulgaris fruit 
      in patients with type 2 diabetes for 12 weeks has beneficial anti-inflammatory, 
      anti-hyperglycemic, and anti-hyperlipidemic effects on type 2 diabetes mellitus 
      [T2DM] patients compared to the control group. Thus, it seems reasonable to 
      design a large-scale clinical trial to determine the potential adverse effects of 
      higher doses of this fruit and identify the therapeutic doses for the 
      complementary treatment in T2DM medication. The medication with this popular 
      fruit as an ingredient could be easily accepted by diabetic patients and may 
      reduce the dependency and dosage of some of the routine diabetes medications 
      which often have some adverse side effects.
CI  - (c) 2020 Wiley Periodicals, Inc.
FAU - Irannejad Niri, Zahra
AU  - Irannejad Niri Z
AD  - Department of Nutrition, School of Public Health, Iran University of Medical 
      Sciences, Tehran, Iran.
FAU - Shidfar, Farzad
AU  - Shidfar F
AUID- ORCID: 0000-0002-6531-9253
AD  - Department of Nutrition, School of Public Health, Iran University of Medical 
      Sciences, Tehran, Iran.
FAU - Jabbari, Masoumeh
AU  - Jabbari M
AD  - Student Research Committee, Faculty of Nutrition Sciences and Food Industry, 
      Department of Community Nutrition, Shahid Beheshti University of Medical 
      Sciences, Tehran, Iran.
FAU - Zarrati, Mitra
AU  - Zarrati M
AD  - Department of Nutrition, School of Public Health, Iran University of Medical 
      Sciences, Tehran, Iran.
FAU - Hosseini, AghaFateme
AU  - Hosseini A
AD  - Department of Biostatistics, School of Public Health, Iran University of Medical 
      Sciences, Tehran, Iran.
FAU - Malek, Mojtaba
AU  - Malek M
AD  - Research Center for Prevention of Cardiovascular Disease, Institute of 
      Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran.
FAU - Dehnad, Afsaneh
AU  - Dehnad A
AD  - Department of English Language, School of Health Management and Information 
      Sciences, Iran University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200330
PL  - United States
TA  - J Food Biochem
JT  - Journal of food biochemistry
JID - 7706045
RN  - 0 (Lipids)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - C-Reactive Protein
MH  - *Diabetes Mellitus, Type 2
MH  - Humans
MH  - Lipids
MH  - *Ziziphus/adverse effects
OTO - NOTNLM
OT  - Z. vulgaris
OT  - glycemic control
OT  - inflammation
OT  - lipid profile
OT  - type 2 diabetes mellitus
EDAT- 2020/04/01 06:00
MHDA- 2021/07/09 06:00
CRDT- 2020/04/01 06:00
PHST- 2020/02/12 00:00 [revised]
PHST- 2019/08/22 00:00 [received]
PHST- 2020/02/15 00:00 [accepted]
PHST- 2020/04/01 06:00 [pubmed]
PHST- 2021/07/09 06:00 [medline]
PHST- 2020/04/01 06:00 [entrez]
AID - 10.1111/jfbc.13193 [doi]
PST - ppublish
SO  - J Food Biochem. 2021 Mar;45(3):e13193. doi: 10.1111/jfbc.13193. Epub 2020 Mar 30.